Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT03191175 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus

Inflammasome Activation Via Circulating Metabolites

InflammoVIH
Start date: June 2017
Phase: N/A
Study type: Observational

The clinical challenges confronting patients with HIV has shifted over the past 10 years from acquired immunodeficiency syndrome to chronic diseases including atherosclerosis, neurocognitive disorders, and osteoporosis. Chronic low grade inflammation and monocyte activation have been consistently associated with comorbidities in HIV patients. Indeed, recent studies indicate that inflammatory mediators including IL-6, IL-1, sCD14 and s CD163 produced by monocytes, but not T-cell activation, predict Non-AIDS-related events in virologically suppressed HIV-infected persons treated with combined antiretroviral therapy (cART), highlighting the important role of monocyte activation in the occurrence of comorbidities in cART-treated HIV infected patients. Yet, the underlying molecular pathways of persistent monocyte activation in cART treated HIV-infected patients remains incompletely characterized. Our preliminary results: 1/ establish a link between the activation of the inflammasome, the increased of pyrimidine-derived metabolites and the cardiovascular risk in a cohort of elderly patients; 2/ show that treated HIV-patients are characterized by increased soluble IL-1b or IL-18 in their blood suggesting that the inflammasome pathway is activated. Objectives: In this study we will characterize the molecular pathways underlying persistent monocyte activation in treated HIV patients, through the implication of the activation of the inflammasome machinery: 1. Characterization of NOD like Receptor (NLR) expression in monocytes for IL-1b and IL-18 secretion (inflammasome activation); 2. Characterization of circulating metabolites that active the inflammasome machinery; 3. Evaluation of the link between the activation of the inflammasome, the increased of circulating metabolites and the non-AIDS related comorbidities.

NCT ID: NCT03190317 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus

Health Information for Infected Veterans

HI-FIV
Start date: August 2017
Phase: N/A
Study type: Observational

This is a study of study of My HealtheVet (MHV) use by Veterans diagnosed with Human Immunodeficiency Virus (HIV) and VA providers/staff who care for them. We hope to learn and understand how MHV can improve the self-management of chronic conditions like HIV. First, we will review Veteran medical records to look at the relationship between use of MHV and whether it has a positive or negative impact on the Veteran's management of HIV. Next, we will interview Veterans to find out how they use MHV for self-management and both Veterans and providers to find out why they choose to use (or not to use) specific MHV tools. Lastly, we will use the information we found from the first two steps and create an intervention that will encourage non-MHV users to use the MHV tools that can help them achieve their health-related goals. Once the intervention has been developed, Veterans and providers will participate in a "cognitive walkthrough" where they will help the researchers test the intervention to see if it is usable, possible, and acceptable.

NCT ID: NCT03189394 Not yet recruiting - HIV Infections Clinical Trials

A Randomized Trial to Prevent HIV Among Gay Couples (PRIDE)

PRIDE
Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

The proposed study is a randomized controlled intervention to reduce sexual risk for HIV among HIV-negative concordant and HIV discordant gay couples. There are three arms of the study: 1) the in-person experimental condition, PRIDE, 2) the online adaptation of the experimental condition, ePRIDE, and 3) the time- and attention-matched in-person control condition, Men's Health. Participants (N = 300 couples) will be randomized equally into one of the three study conditions and assessed via surveys at baseline and at 3-, 6- and 9-months after completion of the intervention sessions.

NCT ID: NCT03182738 Recruiting - Clinical trials for HIV (Human Immunodeficiency Virus)

Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms

VIP-HANA
Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to use technology to improve symptom status and ultimately improve patient centered outcomes in people living with HIV/AIDS (PLWHA). The primary purpose of the intervention (VIP-HANA) is to improve symptom status. The investigators hypothesize that VIP-HANA will improve symptom frequency and intensity.

NCT ID: NCT03181789 Not yet recruiting - HIV Infections Clinical Trials

Evaluating the Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA by Intramuscular Electroporation, in Healthy, HIV-Uninfected Adults

HVTN 119
Start date: July 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of two HIV-1 pDNA vaccines: p24CE1/2 pDNA and p55^gag pDNA administered with IL-12 pDNA adjuvant, given by intramuscular (IM) injection with electroporation (EP), in healthy, HIV-uninfected adults.

NCT ID: NCT03167606 Recruiting - HIV Infections Clinical Trials

A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM

Start date: October 2017
Phase: N/A
Study type: Interventional

The proposed MyPEEPS Mobile intervention is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information specifically developed for at-risk young men who have sex with men (YMSM). This will be the one of the first studies to test the efficacy of a scaled-up, mobile version of an existing human immunodeficiency virus (HIV) prevention intervention originally developed for, designed by, and piloted for, a diverse group of YMSM. MyPEEPS Mobile will be tested in an randomized controlled trial with racially and ethnically diverse HIV-negative or unknown status YMSM aged 13-18 at four geographically diverse sites: Birmingham, Chicago, New York City, and Seattle, allowing for increased generalizability of findings.

NCT ID: NCT03164564 Not yet recruiting - HIV Infections Clinical Trials

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Start date: October 2017
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.

NCT ID: NCT03164447 Not yet recruiting - HIV-1 Infection Clinical Trials

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

Start date: September 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the efficacy, safety, and tolerability of UB-421 in conjunction with an existing failing antiretroviral therapy (ART) for 2 weeks and optimized background therapy (OBT) for 24 weeks, respectively.

NCT ID: NCT03162965 Recruiting - Clinical trials for Human Immunodeficiency Virus

Innovations in HIV Testing

TI
Start date: December 1, 2016
Phase: N/A
Study type: Interventional

The investigators propose to improve HIV prevention and care through expanding HIV testing options to include self-testing for young women, their peers and their sex partners, and by facilitating linkage to care.

NCT ID: NCT03161444 Recruiting - HIV Infections Clinical Trials

Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.

ZIKAVIH
Start date: March 21, 2017
Phase: N/A
Study type: Interventional

This study will estimate the cumulative incidence of Zika infection at the end of the first epidemic in the French West Indies in a sample of patients followed for HIV infection.